New Catheter-Based valve repair could help heart patients avoid surgery
NCT ID NCT03382457
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a device called the Edwards Cardioband FIT, which is used to repair the tricuspid valve in people with tricuspid regurgitation (a leaky heart valve). The device is delivered through a catheter, avoiding open-heart surgery. The trial includes 75 participants with moderate or worse tricuspid regurgitation who still have symptoms despite medical therapy. The goal is to see if the device is safe and effective at reducing the leak and improving symptoms.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Edwards Cardioband FIT Valve Repair System (a device implanted via catheter to repair the tricuspid valve)
- What this could lead to
- If it works, this could offer a less invasive treatment option for people with tricuspid regurgitation, reducing symptoms and the need for open-heart surgery.
- What could go wrong
- This is an early-stage study with only 75 participants, so results may not apply to everyone. The procedure carries risks like bleeding, infection, or device complications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 75 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2018
- Expected to finish
-
Dec 2031
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Tricuspid regurgitation (moderate or greater) * Despite medical therapy, per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR. * The local site Heart Team determines that the patient is appropriate for transcatheter tricuspid reconstruction * Patient is willing and able to comply with all specified study evaluations and provides written informed consent Key Exclusion Criteria: Patients with conditions or anatomical considerations that preclude safe and successful procedure-related or study device access, deployment, or function, including but not limited to: * Patients in whom transesophageal echocardiography is contraindicated or cannot be completed. * Patients in whom tricuspid valve anatomy is not evaluable by TTE or TEE * Untreatable hypersensitivity or contraindication to any of the following: all antiplatelets, all anticoagulants, nitinol alloys (nickel and titanium), polyester, or contrast media. * Previous tricuspid valve repair or replacement with device in place * Presence of trans-tricuspid pacemaker or defibrillator leads where: (a)TR is a result of impingement on the tricuspid valve leaflet as evaluated by echocardiography; or (b) implanted in the RV within the last 90 days Primary tricuspid valve disease Any physical impairment which limits the patient's capacity to complete functional testing due to other medical conditions independent of their TR (e.g., orthopedic condition) Currently participating in another investigational biologic, drug, or device study Any of the following cardiovascular procedures: * Percutaneous coronary, intracardiac, or endovascular intervention within the last 30 days * Carotid surgery within the last 30 days * Direct current cardioversion within the last 30 days * Leadless RV pacemaker implant within the last 30 days * Cardiac surgery within the last 90 days Any of the following underlying medical conditions: * Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation * Active endocarditis or infection requiring antibiotic therapy (oral or intravenous) * Hemodynamically significant pericardial effusion * Significant intra-cardiac mass, thrombus, or vegetation * Untreated clinically significant coronary artery disease (CAD) requiring revascularization, evidence of acute coronary syndrome, or recent myocardial infarction (MI) * Known history of untreated severe symptomatic carotid stenosis (\>50% by ultrasound) or asymptomatic carotid stenosis (\>70% by ultrasound) * Hypotension (systolic pressure \<90 mmHg) or requirement for inotropic support or hemodynamic support within the last 30 days * Known bleeding or clotting disorders or patient refuses blood transfusion * Active GI bleeding * Recent stroke * Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months or any planned percutaneous cardiac procedure within the next 90 days * Deep vein thrombosis (DVT) or pulmonary embolism (PE) in the last 6 months Pregnant, breastfeeding, or planning pregnancy within the next 12 months Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Tricuspid regurgitation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Medical Center /New York Presbyterian Hospital
New York, New York, 10032, United States
-
Heart Hospital Baylor Plano
Plano, Texas, 75093, United States
-
Intermountain Medical Center
Murray, Utah, 84107, United States
-
Lankenau Medical Center
Wynnewood, Pennsylvania, 19096, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Morristown Medical Center
Morristown, New Jersey, 07962, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Oregon Health & Science University
Portland, Oregon, 97293, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Lung and liver scans could map hidden heart valve disease
- Jugular vein approach tested for replacing leaky heart valve without open surgery
- Pacemaker showdown: which device spares the Heart's valve?
- Can a tiny heart implant fix a leaky valve without surgery?
- Can a catheter valve replace Open-Heart surgery for a leaky heart valve?
- A new Catheter-Based valve could fix a leaky heart valve without surgery